Ken Griffin Eye Point Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,135,389 shares of EYPT stock, worth $25.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,135,389

Previous 2,344,210 8.91%

Holding current value

$25.3 Million

Previous $22.1 Million 33.97%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$9.01 - $14.19 $1.88 Million - $2.96 Million	-208,821 Reduced 8.91%	2,135,389 $29.6 Million
Q2 2025 Aug 14, 2025	BUY	$4.13 - $10.54 $240,039 - $612,595	58,121 Added 2.54%	2,344,210 $22.1 Million
Q1 2025 May 15, 2025	SELL	$5.42 - $9.22 $979,811 - $1.67 Million	-180,777 Reduced 7.33%	2,286,089 $12.4 Million
Q4 2024 Feb 14, 2025	BUY	$7.02 - $12.12 $7.44 Million - $12.8 Million	1,059,513 Added 75.28%	2,466,866 $18.4 Million
Q3 2024 Nov 14, 2024	BUY	$7.58 - $10.54 $400,383 - $556,733	52,821 Added 3.9%	1,407,353 $11.2 Million

Q2 2024 Aug 14, 2024	SELL	$8.16 - $22.89 $171,237 - $480,346	-20,985 Reduced 1.53%	1,354,532 $11.8 Million
Q1 2024 May 15, 2024	BUY	$19.93 - $29.71 $2.95 Million - $4.4 Million	148,239 Added 12.08%	1,375,517 $28.4 Million
Q4 2023 Feb 14, 2024	BUY	$5.71 - $24.13 $960,599 - $4.06 Million	168,231 Added 15.89%	1,227,278 $28.4 Million
Q3 2023 Nov 14, 2023	BUY	$7.99 - $15.36 $1.69 Million - $3.25 Million	211,284 Added 24.92%	1,059,047 $8.46 Million
Q2 2023 Aug 14, 2023	SELL	$3.03 - $9.0 $212,866 - $632,277	-70,253 Reduced 7.65%	847,763 $7.38 Million
Q1 2023 May 15, 2023	BUY	$2.28 - $5.04 $818,811 - $1.81 Million	359,128 Added 64.26%	918,016 $2.7 Million
Q4 2022 Feb 14, 2023	BUY	$2.37 - $7.2 $284,437 - $864,115	120,016 Added 27.35%	558,888 $1.96 Million
Q3 2022 Nov 14, 2022	SELL	$6.96 - $11.12 $4.19 Million - $6.7 Million	-602,145 Reduced 57.84%	438,872 $3.47 Million
Q2 2022 Aug 15, 2022	SELL	$7.25 - $12.71 $3.11 Million - $5.46 Million	-429,279 Reduced 29.2%	1,041,017 $8.19 Million
Q1 2022 May 16, 2022	BUY	$8.67 - $14.11 $9,389 - $15,281	1,083 Added 0.07%	1,470,296 $17.9 Million
Q4 2021 Feb 14, 2022	BUY	$10.18 - $18.4 $5.32 Million - $9.62 Million	522,789 Added 55.24%	1,469,213 $18 Million
Q3 2021 Nov 15, 2021	SELL	$7.51 - $11.72 $86,072 - $134,322	-11,461 Reduced 1.2%	946,424 $9.86 Million
Q2 2021 Aug 16, 2021	SELL	$8.69 - $11.08 $675,378 - $861,126	-77,719 Reduced 7.5%	957,885 $8.61 Million
Q1 2021 May 17, 2021	BUY	$8.89 - $14.92 $9.08 Million - $15.2 Million	1,021,727 Added 7362.74%	1,035,604 $10.5 Million
Q4 2020 Feb 16, 2021	BUY	$3.7 - $6.58 $51,344 - $91,310	13,877 New	13,877 $91,000

Others Institutions Holding EYPT

# of Institutions

167

Shares Held

68M

Call Options Held

421K

Put Options Held

401K

View Full List

About EyePoint Pharmaceuticals, Inc.

Ticker EYPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,072,200
Market Cap $404M
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...

More about EYPT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account